A multicolour fluorescence <i>in situ</i> hybridization test predicts recurrence in patients with high‐risk superficial bladder tumours undergoing intravesical therapy

Abstract

In patients with high-risk superficial bladder tumours undergoing IVT, a positive UroVysion test after treatment is highly predictive of recurrence, even in a multivariate model. Additional adjuvant therapy might be necessary in these patients to improve the outcome.